3 New Catalysts for Palantir's High-Flying Stock : vimarsana

3 New Catalysts for Palantir's High-Flying Stock


Palantir's (NYSE:PLTR) stock has roughly tripled in price since its direct listing three months ago. Interest in the data-mining firm's stock was initially tepid due to its controversial business model, heavy dependence on government contracts, lack of profits, and ongoing insider sales.
However, Palantir's third-quarter earnings report in November -- which featured accelerating revenue growth, expanding gross margins, new government contracts, and enterprise renewals -- attracted a stampede of bulls.
Palantir's stock now trades at nearly 40 times next year's sales, and some analysts are warning that the stock could be too hot to handle. That caution is warranted, but three recent developments have kept the bulls engaged over the past month.

Related Keywords

United Kingdom , British , , Uk National Health Service , Oncology Center , Us Army , Drug Administration , Army Vantage , Drug Evaluation , Public Sector Government Innovation Award , Health Service , ஒன்றுபட்டது கிஂக்டம் , பிரிட்டிஷ் , இங்கிலாந்து தேசிய ஆரோக்கியம் சேவை , புற்றுநோயியல் மையம் , எங்களுக்கு இராணுவம் , இராணுவம் வ்யாஂடேஜ் , மருந்து மதிப்பீடு , பொது துறை அரசு கண்டுபிடிப்பு விருது , ஆரோக்கியம் சேவை ,

© 2025 Vimarsana